



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/089,625	01/08/2003	Suk-Jin Koo	57167/7-1970	1429
21874	7590	11/14/2003	EXAMINER	
EDWARDS & ANGELL, LLP			FORD, JOHN M	
P.O. BOX 9169			ART UNIT	PAPER NUMBER
BOSTON, MA 02209			1624	

DATE MAILED: 11/14/2003

9

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No. <i>10/089625</i>	Applicant(s) <i>Koo et al</i>
Examiner <i>J.M. Ford</i>	Group Art Unit <i>1624</i>

—The MAILING DATE of this communication appears on the cover sheet beneath the correspondence address—

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE ONE MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, such period shall, by default, expire SIX (6) MONTHS from the mailing date of this communication .
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).

**Status**

- Responsive to communication(s) filed on \_\_\_\_\_.
- This action is **FINAL**.
- Since this application is in condition for allowance except for formal matters, **prosecution as to the merits is closed** in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

**Disposition of Claims**

Claim(s) 1 -- 12 is/are pending in the application.

Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

- Claim(s) \_\_\_\_\_ is/are allowed.
- Claim(s) \_\_\_\_\_ is/are rejected.
- Claim(s) \_\_\_\_\_ is/are objected to.
- Claim(s) 1 -- 12 are subject to restriction or election requirement.

**Application Papers**

- See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.
- The proposed drawing correction, filed on \_\_\_\_\_ is  approved  disapproved.
- The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.
- The specification is objected to by the Examiner.
- The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. § 119 (a)-(d)**

- Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
  - All  Some\*  None of the CERTIFIED copies of the priority documents have been received.
  - received in Application No. (Series Code/Serial Number) \_\_\_\_\_.
  - received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_.

**Attachment(s)**

- Information Disclosure Statement(s), PTO-1449, Paper No(s). \_\_\_\_\_
- Interview Summary, PTO-413
- Notice of Reference(s) Cited, PTO-892
- Notice of Informal Patent Application, PTO-152
- Notice of Draftsperson's Patent Drawing Review, PTO-948
- Other \_\_\_\_\_

**Office Action Summary**

Applicants' response of September 30, 2003, replaced all the original versions of the claims to a different set of claims directed to different inventions.

37 CFR 1.145 prohibits changing the subject matter once a <sup>first</sup> action on the merits is issued.

The <sup>original</sup> claims were to thiazines, now applicants present pyrimidines with pyrido sulfonamides.

If I permit a shift of invention to pyrimidines with pyrido sulfonamides, I am given no additional time to do a first action on the merits.

I cannot also examine claim 6, as it does not have the <sup>pyrimidine</sup>, which controls the classification and search, now that the thiazine is not present.

Accordingly, restriction is required between:

Group I;claims 1—5, drawn to pyrimidines in class 544. Claims 8—12 will be examined therewith.

Group II;claims 6 and 7, drawn to pyridines in class 546.

This application has been found to contain more than one invention. Therefore, restriction to one compound invention is required:

These distinct inventions have acquired separate status in the art, will support separate patents, and will require different fields of search for the respective inventions. Accordingly, restriction for examination purposes, as indicated, is considered proper.

Applicants' response must include a provisional election, even if the requirement be traversed in order to be held responsive.

J. M. Ford:jmr

November 10, 2003



JOHN M. FORD  
PRIMARY EXAMINER



Nov 10 2003